Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-lindau disease: Targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors
Dive into the research topics of 'Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-lindau disease: Targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors'. Together they form a unique fingerprint.